GIRANDA VL[au] - Search Results

Year	Number of Results
1986	1
1988	1
1989	1
1990	1
1992	1
1994	2
1995	1
1996	1
1998	1
1999	1
2000	3
2001	4
2002	1
2003	1
2004	6
2005	4
2006	9
2007	5
2008	9
2009	10
2010	3
2011	1
2012	3
2014	3
2015	1
2016	1
2017	1
2019	1
2022	0

1

Optimal two-stage designs for exploratory basket trials.

Zhou H, Liu F, Wu C, Rubin EH, Giranda VL, Chen C. Zhou H, et al. Among authors: giranda vl. Contemp Clin Trials. 2019 Oct;85:105807. doi: 10.1016/j.cct.2019.06.021. Epub 2019 Jun 29. Contemp Clin Trials. 2019. PMID: 31260789

2

Inhibitors of the proteolytic activity of urokinase type plasminogen activator.

Rockway TW, Giranda VL. Rockway TW, et al. Among authors: giranda vl. Curr Pharm Des. 2003;9(19):1483-98. doi: 10.2174/1381612033454649. Curr Pharm Des. 2003. PMID: 12871064 Review.

3

Inhibitors of the protease domain of urokinase-type plasminogen activator.

Rockway TW, Nienaber V, Giranda VL. Rockway TW, et al. Among authors: giranda vl. Curr Pharm Des. 2002;8(28):2541-58. doi: 10.2174/1381612023392676. Curr Pharm Des. 2002. PMID: 12369939 Review.

4

Structure-based drug design of antirhinoviral compounds.

Giranda VL. Giranda VL. Structure. 1994 Aug 15;2(8):695-8. doi: 10.1016/s0969-2126(00)00069-1. Structure. 1994. PMID: 7994569 Review.

5

PARP inhibitors attenuate chemotherapy-induced painful neuropathy.

Brederson JD, Joshi SK, Browman KE, Mikusa J, Zhong C, Gauvin D, Liu X, Shi Y, Penning TD, Shoemaker AR, Giranda VL. Brederson JD, et al. Among authors: giranda vl. J Peripher Nerv Syst. 2012 Sep;17(3):324-30. doi: 10.1111/j.1529-8027.2012.00413.x. J Peripher Nerv Syst. 2012. PMID: 22971094

6

Crystallographic quaternary structural analysis of AMP nucleosidases from Escherichia coli and Azotobacter vinelandii.

Giranda VL, Berman HM, Schramm VL. Giranda VL, et al. J Biol Chem. 1989 Sep 15;264(26):15674-80. J Biol Chem. 1989. PMID: 2670945 Free article.

7

Chkl binds and phosphorylates BAD protein.

Han EK, Butler C, Zhang H, Severin JM, Qin W, Holzman TF, Gubbins EJ, Simmer RL, Rosenberg S, Giranda VL, Ng SC, Luo Y. Han EK, et al. Among authors: giranda vl. Anticancer Res. 2004 Nov-Dec;24(6):3907-10. Anticancer Res. 2004. PMID: 15736430 Free article.

8

Hit to Lead optimization of a novel class of squarate-containing polo-like kinases inhibitors.

Zhang Q, Xia Z, Mitten MJ, Lasko LM, Klinghofer V, Bouska J, Johnson EF, Penning TD, Luo Y, Giranda VL, Shoemaker AR, Stewart KD, Djuric SW, Vasudevan A. Zhang Q, et al. Among authors: giranda vl. Bioorg Med Chem Lett. 2012 Dec 15;22(24):7615-22. doi: 10.1016/j.bmcl.2012.10.009. Epub 2012 Oct 11. Bioorg Med Chem Lett. 2012. PMID: 23103095

9

Discovery and SAR of orally efficacious tetrahydropyridopyridazinone PARP inhibitors for the treatment of cancer.

Zhu GD, Gong J, Gandhi VB, Liu X, Shi Y, Johnson EF, Donawho CK, Ellis PA, Bouska JJ, Osterling DJ, Olson AM, Park C, Luo Y, Shoemaker A, Giranda VL, Penning TD. Zhu GD, et al. Among authors: giranda vl. Bioorg Med Chem. 2012 Aug 1;20(15):4635-45. doi: 10.1016/j.bmc.2012.06.021. Epub 2012 Jun 19. Bioorg Med Chem. 2012. PMID: 22766219

10

Population pharmacokinetic modeling of veliparib (ABT-888) in patients with non-hematologic malignancies.

Salem AH, Giranda VL, Mostafa NM. Salem AH, et al. Among authors: giranda vl. Clin Pharmacokinet. 2014 May;53(5):479-88. doi: 10.1007/s40262-013-0130-1. Clin Pharmacokinet. 2014. PMID: 24452810 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results